Best supportive care versus palliative chemotherapy in nonsmall-cell lung cancer

被引：12

作者：

Medley, L ^{[1
]}

Cullen, M ^{[1
]}

机构：

[1] Univ Hosp Birmingham NHS Trust, Queen Elizabeth Hosp, Ctr Canc, Birmingham, W Midlands, England

来源：

CURRENT OPINION IN ONCOLOGY | 2002年 / 14卷 / 04期

关键词：

D O I：

10.1097/00001622-200207000-00002

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The incidence of lung cancer continues to rise. The need and demand for more effective treatment to improve survival and palliate symptoms increases at a great rate. The most recent evidence for the use of chemotherapy in the palliative setting is summarized in this review of the literature from the last few years. It indicates that in advanced nonsmall-cell lung cancer survival, symptom control and physical functioning can be improved with the use of chemotherapy not only in the first-line but also in the second-line setting, in the elderly, and at disease relapse. (C) 2002 Lippincott Williams Wilkins, Inc.

引用

页码：384 / 388

页数：5

共 27 条

[1] Gemcitabine plus best supportive care (BSC) vs BSC in inoperable non-small cell lung cancer - a randomized trial with quality of life as the primary outcome [J].

Anderson, H. ;

Hopwood, P. ;

Stephens, R. J. ;

Thatcher, N. ;

Cottier, B. ;

Nicholson, M. ;

Milroy, R. ;

Maughan, T. S. ;

Falk, S. J. ;

Bond, M. G. ;

Burt, P. A. ;

Connolly, C. K. ;

McIllmurray, M. B. ;

Carmichael, J. .

BRITISH JOURNAL OF CANCER, 2000, 83 (04) :447-453

[2]

Archer V R, 1999, Oncologist, V4, P470

[3]

Belani C, 2001, SEMIN ONCOL, V28, P10, DOI [10.1053/sonc.2001.24602, 10.1053/sonc.20901.18403]

[4] Interim analysis of a phase II study of induction weekly paclitaxel/carboplatin regimens followed by maintenance weekly paclitaxel for advanced and metastatic non-small cell lung cancer [J].

Belani, CP .

SEMINARS IN ONCOLOGY, 2001, 28 (04) :14-16

[5] The benefits of chemotherapy in patient subgroups with unresectable non-small-cell lung cancer [J].

Billingham, LJ ;

Cullen, MH .

ANNALS OF ONCOLOGY, 2001, 12 (12) :1671-1675

[6] Novel approaches for the treatment of non-small cell lung cancer [J].

Bonomi, P .

SEMINARS IN ONCOLOGY, 2001, 28 (04) :45-49

[7] Mitomycin, ifosfamide, and cisplatin in unresectable non-small-cell lung cancer: Effects on survival and quality of life [J].

Cullen, MH ;

Billingham, LJ ;

Woodroffe, CM ;

Chetiyawardana, AD ;

Gower, NH ;

Joshi, R ;

Ferry, DR ;

Rudd, RM ;

Spiro, SG ;

Cook, JE ;

Trask, C ;

Bessell, E ;

Connolly, CK ;

Tobias, J ;

Souhami, RL .

JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (10) :3188-3194

[8]

CULLEN MH, 2001, LANCET ONCOLOGY, V3, P173

[9] Gemcitabine and carboplatin for patients with advanced non-small cell lung cancer [J].

Dómine, M ;

Casado, V ;

Estévez, LG ;

León, A ;

Martin, JI ;

Castillo, M ;

Rubio, G ;

Lobo, F .

SEMINARS IN ONCOLOGY, 2001, 28 (03) :4-9

[10] Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens [J].

Fossella, FV ;

DeVore, R ;

Kerr, RN ;

Crawford, J ;

Natale, RR ;

Dunphy, F ;

Kalman, L ;

Miller, V ;

Lee, JS ;

Moore, M ;

Gandara, D ;

Karp, D ;

Vokes, E ;

Kris, M ;

Kim, Y ;

Gamza, F ;

Hammershaimb, L .

JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (12) :2354-2362

← 1 2 3 →